Cell Signaling Technology, Inc.

09/07/2026

⚡🔬Planning your next experiment to examine cancer metabolism? Start with the pathways tumors most commonly hijack—glycolysis, glutamine metabolism, lipid metabolism, and hypoxia signaling.

🔗 Explore key metabolic signaling targets, pathways, and antibody tools for Deregulating Cellular Metabolism on the .

Learn how cancer cells reprogram metabolism through hypoxia, the Warburg effect, autophagy, glutamine, and lipid pathways for enhanced growth and survival.

09/03/2026

Expectation: Cancer cells undergo cell death.
Observation: Cancer cells survive.

Why is that? Learn whether Bcl-2 family members are contributing to cell death resistance with antibody sampler kits from CST: https://hubs.ly/Q042ymtL0

09/02/2026

A versatile, no-wash assay that’s amenable to high‑throughput, automated drug discovery workflows? That’s TR-FRET in action.

In the latest , we show how CST antibodies and matched pairs can support:

- Protein quantification
- TPD degradation & ubiquitination assays
- Target engagement & ternary complex readouts
- Competition formats for small‑molecule binding

Learn how to configure Eu‑based TR‑FRET assays across your discovery pipeline:

Explore TR‑FRET assay formats for drug discovery, from antibody pair‑based quantification to TPD degradation, ubiquitination, engagement, and competition assays.

09/02/2026

💀🧰 Apoptosis isn’t the whole story. Other programmed cell death pathways—such as necroptosis, ferroptosis, and pyroptosis—can also influence cancer progression.

👉 Build your cell death research toolbox with key markers and antibody tools for apoptosis and other regulated cell death pathways using the .

Discover how cancer cells evade apoptosis and other death pathways and explore key targets, markers and tools to study the Hallmark of Resisting Cell Death

08/28/2026

🔥🔬 Examining the effects of chronic inflammation in the TME? Start with the pathways that link inflammation to cancer—NF‑κB, IL‑6/JAK/STAT3, and inflammasome signaling.

👉 Explore pathway diagrams and IHC‑validated CST® antibodies for Tumor‑Promoting Inflammation, including markers for MDSCs, TAMs, TANs, and NETs, on the .

Cancer cells hijack inflammatory mechanisms to promote their own growth and survival.

08/26/2026

At CST, every antibody is tested multiple times. And we share that testing data on our product pages just the way we see it. To validate the performance of our antibodies, we examine the biological context, expression levels, disease models, tissue types, and applications you’re likely to use. That’s why we can guarantee they’ll work as intended—every time. And give you results that are accurate and reproducible. Why gamble with anything else?
https://hubs.ly/Q04vq-L80

08/25/2026

Parkinson’s doesn’t occur due to one mechanism failing.
Explore our pathway diagram to see how lysosomal processing, mitochondrial dysfunction, ER stress, and the aggregation & phosphorylation of α-synuclein correlate with disease onset and progression. https://hubs.ly/Q04n3tKm0

08/25/2026

Determining whether the DNA homologous repair pathway is functioning or not is important, since that knowledge can be used in the treatment of BRCA1/2 cancers 🛠️

Use CST® Rad51 antibodies to identify Rad51 foci, a key indicator of an active HR pathway: https://hubs.ly/Q042yp1L0

08/19/2026

🔬 Turning visually stunning multiplex images into robust spatial data doesn’t have to mean buying a closed system or rebuilding your workflow from scratch. On the latest , we walk through how to:

- Co‑register multi‑cycle images
- Perform cell detection and segmentation
- Export cell‑level data for downstream spatial analysis

Get expert insights👇

Learn how to quantify SignalStar Multiplex IHC data in QuPath, from image co-registration and cell segmentation to exporting cell-level spatial biology insights.

08/18/2026

🛑🔬 Studying downstream effects using a tumor suppressor knockout model?

Explore the tumor suppressor nodes, key pathways, and IHC-validated CST® antibodies for Evading Growth Suppressors on the . 👉

Learn how tumor suppressors like Rb, p53, PTEN, and CDKN2A act as molecular brakes on cell division in the Cancer Hallmark Evading Growth Surpressors.